Cargando…

Relapsing De Novo Membranous Nephropathy

Allograft membranous glomerulopathy can be a recurrent or de novo disease. Both instead have different underlying immune pathophysiology and disease pattern. While the introduction of ANTI-PLAR2 and THS7A brought new insights into the management of Immune/primary MN, the treatment of de novo MN is n...

Descripción completa

Detalles Bibliográficos
Autores principales: Ali, Ala, Al-Taee, Huda, Kadhim, Thaer J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9085326/
https://www.ncbi.nlm.nih.gov/pubmed/35547830
http://dx.doi.org/10.1155/2022/6754520
_version_ 1784703790102872064
author Ali, Ala
Al-Taee, Huda
Kadhim, Thaer J.
author_facet Ali, Ala
Al-Taee, Huda
Kadhim, Thaer J.
author_sort Ali, Ala
collection PubMed
description Allograft membranous glomerulopathy can be a recurrent or de novo disease. Both instead have different underlying immune pathophysiology and disease pattern. While the introduction of ANTI-PLAR2 and THS7A brought new insights into the management of Immune/primary MN, the treatment of de novo MN is not clear. Relapsing de novo MN in a kidney transplant was rarely reported. Here, we present a case of relapsing de novo MN without evidence of rejection and a gratifying response to rituximab.
format Online
Article
Text
id pubmed-9085326
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-90853262022-05-10 Relapsing De Novo Membranous Nephropathy Ali, Ala Al-Taee, Huda Kadhim, Thaer J. Case Rep Transplant Case Report Allograft membranous glomerulopathy can be a recurrent or de novo disease. Both instead have different underlying immune pathophysiology and disease pattern. While the introduction of ANTI-PLAR2 and THS7A brought new insights into the management of Immune/primary MN, the treatment of de novo MN is not clear. Relapsing de novo MN in a kidney transplant was rarely reported. Here, we present a case of relapsing de novo MN without evidence of rejection and a gratifying response to rituximab. Hindawi 2022-05-02 /pmc/articles/PMC9085326/ /pubmed/35547830 http://dx.doi.org/10.1155/2022/6754520 Text en Copyright © 2022 Ala Ali et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Ali, Ala
Al-Taee, Huda
Kadhim, Thaer J.
Relapsing De Novo Membranous Nephropathy
title Relapsing De Novo Membranous Nephropathy
title_full Relapsing De Novo Membranous Nephropathy
title_fullStr Relapsing De Novo Membranous Nephropathy
title_full_unstemmed Relapsing De Novo Membranous Nephropathy
title_short Relapsing De Novo Membranous Nephropathy
title_sort relapsing de novo membranous nephropathy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9085326/
https://www.ncbi.nlm.nih.gov/pubmed/35547830
http://dx.doi.org/10.1155/2022/6754520
work_keys_str_mv AT aliala relapsingdenovomembranousnephropathy
AT altaeehuda relapsingdenovomembranousnephropathy
AT kadhimthaerj relapsingdenovomembranousnephropathy